Revisiting an old antibiotic: bacitracin neutralizes binary bacterial toxins and protects cells from intoxication.


Journal

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484

Informations de publication

Date de publication:
04 2019
Historique:
pubmed: 31 1 2019
medline: 12 5 2020
entrez: 31 1 2019
Statut: ppublish

Résumé

The antibiotic bacitracin (Bac) inhibits cell wall synthesis of gram-positive bacteria. Here, we discovered a totally different activity of Bac: the neutralization of bacterial exotoxins. Bac prevented intoxication of mammalian cells with the binary enterotoxins Clostridium botulinum C2, C. perfringens ι, C. difficile transferase (CDT), and Bacillus anthracis lethal toxin. The transport (B) subunits of these toxins deliver their respective enzyme (A) subunits into cells. Following endocytosis, the B subunits form pores in membranes of endosomes, which mediate translocation of the A subunits into the cytosol. Bac inhibited formation of such B pores in lipid bilayers in vitro and in living cells, thereby preventing translocation of the A subunit into the cytosol. Bac preserved the epithelial integrity of toxin-treated CaCo-2 monolayers, a model for the human gut epithelium. In conclusion, Bac should be discussed as a therapeutic option against infections with medically relevant toxin-producing bacteria, including C. difficile and B. anthracis, because it inhibits bacterial growth and neutralizes the secreted toxins.-Schnell, L., Felix, I., Müller, B., Sadi, M., von Bank, F., Papatheodorou, P., Popoff, M. R., Aktories, K., Waltenberger, E., Benz, R., Weichbrodt, C., Fauler, M., Frick, M., Barth, H. Revisiting an old antibiotic: bacitracin neutralizes binary bacterial toxins and protects cells from intoxication.

Identifiants

pubmed: 30699302
doi: 10.1096/fj.201802453R
doi:

Substances chimiques

Anti-Bacterial Agents 0
Antigens, Bacterial 0
Bacterial Toxins 0
Exotoxins 0
Lipid Bilayers 0
Protective Agents 0
anthrax toxin 0
Bacitracin 1405-87-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5755-5771

Auteurs

Leonie Schnell (L)

Institute of Pharmacology and Toxicology, University of Ulm Medical Center, Ulm, Germany.

Ina Felix (I)

Institute of Pharmacology and Toxicology, University of Ulm Medical Center, Ulm, Germany.

Bastian Müller (B)

Institute of Pharmacology and Toxicology, University of Ulm Medical Center, Ulm, Germany.

Mirko Sadi (M)

Institute of Pharmacology and Toxicology, University of Ulm Medical Center, Ulm, Germany.

Franziska von Bank (F)

Institute of Pharmacology and Toxicology, University of Ulm Medical Center, Ulm, Germany.

Panagiotis Papatheodorou (P)

Institute of Pharmacology and Toxicology, University of Ulm Medical Center, Ulm, Germany.

Michel R Popoff (MR)

Department of Anaerobic Bacteria, Pasteur Institute, Paris, France.

Klaus Aktories (K)

Institute of Experimental and Clinical Pharmacology and Toxicology, University of Freiburg, Freiburg, Germany.

Eva Waltenberger (E)

Department of Life Sciences and Chemistry, Jacobs University Bremen, Bremen, Germany.

Roland Benz (R)

Department of Life Sciences and Chemistry, Jacobs University Bremen, Bremen, Germany.

Conrad Weichbrodt (C)

Nanion Technologies, Munich, Germany; and.

Michael Fauler (M)

Institute of General Physiology, University of Ulm, Ulm, Germany.

Manfred Frick (M)

Institute of General Physiology, University of Ulm, Ulm, Germany.

Holger Barth (H)

Institute of Pharmacology and Toxicology, University of Ulm Medical Center, Ulm, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH